SeltaSquare Wins 1st Place in AI Drug Development – Safety Category at the '2022 Brand of the Year Award'
페이지 정보
본문
SeltaSquare has won first place in the "AI Drug Development – Safety" category at the 2022 Brand of the Year Award, hosted by JY Network and sponsored by JoongAng Ilbo.
SeltaSquare was founded in July 2021 with the goal of providing differentiated solutions and services that leverage artificial intelligence and digital technologies to enable more proactive and innovative pharmacovigilance (PV) operations.
SELTA-LITUS, launched in July 2021, is an automated adverse event literature monitoring solution that applies the company's proprietary AI algorithms to IBM's Robotic Process Automation (RPA) software, and has been recognized for its innovation. More recently, the company developed and launched SELTA-Tabulator, a one-click automated raw data analysis solution for KIDS (Korea Integrated Drug information Service) data.
In addition, SeltaSquare is developing advanced AI and digital technologies and services designed to help pharmacovigilance professionals minimize repetitive, routine tasks and focus on higher-value work such as risk assessment — all in pursuit of the company's vision to become the new normal in global digital healthcare.
CEO Shin Min-kyung commented: "We are honored to be recognized for our innovation in safety operations through the use of digital technology. Going forward, SeltaSquare will expand its applications into the broader healthcare space and contribute to building a safer, more trustworthy environment for all healthcare recipients."
Read the Original Article : https://www.joongang.co.kr/article/25130542
